Format

Send to

Choose Destination
Cancer Biol Ther. 2014 Jan;15(1):22-5. doi: 10.4161/cbt.26608. Epub 2013 Oct 21.

Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.

Author information

1
Department of Gynecology and Obstetrics; Kyoto University Graduate School of Medicine; Kyoto, Japan.

Abstract

Sorafenib is an oral multikinase inhibitor targeting Raf and other kinases. The anti-tumor effect of sorafenib is thought to be mediated through its inhibition of the RAS-Raf-Erk pathway, as well as its inhibition of VEGFR and PDGFR. Sorafenib has been effective at treating patients with renal cell carcinoma (RCC). Ovarian clear cell carcinoma (OCCC) is a chemoresistant subtype of ovarian cancer. OCCC is represented by cells with clear cytoplasm that resemble those observed in RCC. Using a microarray database, the gene expression profile of OCCC was similar to that of RCC. The effects of sorafenib against human OCCC are unknown. Therefore, we used sorafenib to treat two patients with recurrent chemoresistant OCCC, and observed good effect in both of them without severe side effects. We believe that sorafenib is an effective agent against OCCC. Given the chemoresistant nature of this tumor, this drug appears to be very valuable.

KEYWORDS:

ovarian clear cell carcinoma; progression-free survival; sorafenib

Comment in

PMID:
24096267
PMCID:
PMC3938519
DOI:
10.4161/cbt.26608
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center